血脂正常的急性冠状动脉综合征患者早期辛伐他汀干预的临床研究  

Effect of early intervention of simvastatin in patients with acute coronary syndrome and normal blood lipid

作　　者：翁根龙[1] 

机构地区：[1]江苏省人民医院盛泽分院心内科,江苏吴江215228

出　　处：《心血管康复医学杂志》2012年第1期70-72,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨早期应用辛伐他汀对血脂正常急性冠状动脉综合征(ACS)患者血浆脑钠肽(BNP)、高敏C反应蛋白(hsCRP)及预后的影响。方法:68例血脂正常ACS患者被随机分为常规治疗组(34例,仅常规治疗)、辛伐他汀组(34例,常规治疗基础上加用辛伐他汀20mg/d),疗程6个月。于治疗前、后8周检测血浆BNP、hsCRP水平。所有患者每3个月随访一次,平均随访观察6个月,以住院或观察期间的心血管事件为终点。结果:与治疗前比较,治疗后两组血浆BNP[常规治疗组:(375.15±115.86)pg/ml比(145.65±70.12)pg/ml,辛伐他汀组:(376.38±116.15)pg/ml比(96.57±45.26)pg/ml]、hsCRP[常规治疗组:(30.21±2.76)mg/L比(5.20±1.75)mg/L,辛伐他汀组:(30.16±2.73)mg/L比(4.16±1.12)mg/L]水平均有明显下降(P<0.01),且辛伐他汀组较常规治疗组指标下降更为显著(P<0.01);心血管事件发生率辛伐他汀组明显低于常规治疗组(11.7%比29.4%,P<0.01)。结论:血脂正常的急性冠状动脉综合征患者,早期应用辛伐他汀干预可以显著降低血浆脑钠肽、高敏C反应蛋白水平,减轻炎症反应,稳定动脉粥样硬化斑块,减少心血管事件发生。Objective：To study effect of early application of simvastatin on levels of plasma brain natriuretic peptide（BNP）,high sensitive C-reactive protein（hsCRP） and prognosis in patients with acute coronary syndrome（ACS） and normal blood lipid.Methods：A total of 68 ACS patients with normal blood lipid were randomly divided into routine treatment group（n=34,only received routine treatment） and simvastatin group（n=34,received simvastatin 20 mg/d based on routine treatment）,all patients were treated for six months.Plasma levels of BNP and hsCRP were measured before and eight weeks after treatment.All patients were followed up every three months,average of six months,and cardiovascular events during admission or follow-up were regard as end point.Results：Compared with before treatment,there were significant decrease in plasma levels of BNP [routine treatment group：（375.15±115.86） pg/ml vs.（145.65±70.12） pg/ml,simvastatin group：（376.38±116.15） pg/ml vs.（96.57±45.26） pg/ml]and hsCRP [routine treatment group：（30.21±2.76） mg/L vs.（5.20±1.75） mg/L,simvastatin group：（30.16±2.73） mg/L vs.（4.16±1.12） mg/L]after treatment in both groups（P〈0.01）,and above indicators in simvastatin group were significantly lower than those of routine treatment group after treatment（P〈0.01）;Incidence rate of cardiovascular event in simvastatin group was significantly lower than that of routine treatment group（11.7% vs.29.4%,P〈0.01）.Conclusion：Early application of simvastatin can significantly decrease plasma levels of brain natriuretic peptide and high sensitive C-reactive protein,relieve inflammatory reactions,stabilize atherosclerotic plaque and reduce incidence of cardiovascular events in patients with acute coronary syndrome and normal level of blood lipid.

关 键 词：冠状动脉疾病 辛伐他汀 利钠肽 脑 C反应蛋白质 

分 类 号：R541.4[医药卫生—心血管疾病]